ACVR2A Recombinant Protein: A Core Node of the TGF-β Superfamily Bridging Erythropoiesis and Metabolic Regulation

Author: Senior Product Manager of UA Views：5

This article focuses on the molecular characteristics and signal transduction functions of activin receptor type IIA (ACVR2A), systematically elaborating the molecular mechanisms by which it, as a type II receptor serine/threonine kinase of the TGF-β superfamily, regulates three major physiological processes—erythropoiesis, skeletal muscle mass, and lipid metabolism—through binding to ligands such as activin, myostatin, and GDF11; analyzing its overactivation in ineffective erythropoiesis in β-thalassemia and myelodysplastic syndromes and the therapeutic principles of ligand trap strategies; and exploring its expanded application prospects in pulmonary arterial hypertension, preeclampsia, and metabolic diseases.

Recent Advances
Product Information

Recent Advances

ACVR2A Recombinant Protein: A Core Node of the TGF-β Superfamily Bridging Erythropoiesis and Metabolic Regulation

Summary: This article focuses on the molecular characteristics and signal transduction functions of activin receptor type IIA (ACVR2A), systematically elaborating the molecular mechanisms by which it, as a type II receptor serine/threonine kinase of the TGF-β superfamily, regulates three major physiological processes—erythropoiesis, skeletal muscle mass, and lipid metabolism—through binding to ligands such as activin, myostatin, and GDF11. It analyzes its overactivation in ineffective erythropoiesis in β-thalassemia and myelodysplastic syndromes and the therapeutic rationale of the ligand trap strategy, and discusses its expanding application prospects in pulmonary arterial hypertension, preeclampsia, and metabolic diseases.

I. Molecular Characteristics and Family Positioning of ACVR2A.

ACVR2A (activin receptor IIA) is a core signaling node of the TGF-β superfamily that regulates three key physiological processes—erythropoiesis, skeletal muscle mass, and lipid metabolism—by binding to various ligands including activin, myostatin, and GDF11. Its uniqueness lies in the fact that inhibiting this receptor not only promotes erythroid cell maturation to treat anemia but also simultaneously increases muscle and reduces fat. This “one stone, three birds” biological property is giving rise to a rare dual-track landscape spanning hematological oncology and metabolic diseases. ACVR2A is a type II receptor serine/threonine kinase of the TGF-β superfamily that forms a signal transduction complex with type I receptors such as ALK4 and ALK5, phosphorylating the downstream effector molecules Smad2/3 and thereby regulating gene transcription. The receptor is highly homologous to other family members and shares numerous ligands, but its functional bias in signal output across different tissues constitutes its unique value as a therapeutic target.

II. Protein Structure and Signal Transduction Cascade of ACVR2A.

ACVR2A is essentially a single-pass transmembrane serine/threonine kinase-type receptor composed of three parts: a cysteine-rich extracellular ligand-binding domain, a transmembrane region, and an intracellular kinase domain. Its core function lies in precisely regulating cell proliferation and differentiation through a “ligand-receptor-signal transduction” cascade. The specific mechanism can be divided into three steps. In the signal initiation stage, ligands such as activin, myostatin, and GDF11 bind with high affinity to the extracellular domain of ACVR2A. In the signal transmission stage, the complex recruits type I receptors, and ACVR2A activates the GS domain of type I receptors through phosphorylation. In the regulatory execution stage, the activated type I receptors further phosphorylate downstream Smad2/3 proteins, which then bind to Smad4 and enter the nucleus to regulate target gene expression. Notably, ACVR2A signal transduction has a well-developed negative regulatory mechanism: inhibin, follistatin, and others can block excessive signal activation. Once this balance is disrupted, related physiological dysfunctions may occur, and this regulatory imbalance is precisely the molecular basis of multiple diseases.

III. The Core Role of ACVR2A in the Regulation of Erythropoiesis.

The relationship between ACVR2A and the regulation of erythropoiesis is particularly close. In ineffective erythropoiesis in β-thalassemia and myelodysplastic syndromes, the ACVR2A signaling pathway is overactivated, inhibiting the maturation and differentiation of erythroid progenitor cells and leading to ineffective hematopoiesis characterized by “high output but low maturation rate.” Soluble ACVR2A-Fc fusion protein, as a ligand trap, competitively captures ligands to relieve the inhibition of erythroid differentiation and promote late-stage erythrocyte maturation—this is precisely the mechanism of action of luspatercept. The core logic of this mechanism lies in the fact that Smad2/3 signaling transmitted by ACVR2A in erythroid progenitor cells inhibits the late maturation process, while the ligand trap restores the maturation program by removing excess ligands, thereby increasing the output of functional erythrocytes without increasing the number of erythroid progenitors.

IV. Dual Regulation of ACVR2A in Muscle and Lipid Metabolism.

In the metabolic field, promoting muscle growth and reducing fat accumulation by inhibiting ACVR2A is becoming a research hotspot. Myostatin signaling mediated by ACVR2A exerts negative regulation on the maintenance of skeletal muscle mass, and its inhibition can increase muscle mass and strength; at the same time, this receptor signaling is also involved in the regulation of lipid metabolism and energy balance. This dual effect of “building muscle and reducing fat” gives it a potential advantage over single-pathway drugs in the treatment of metabolic diseases. Particularly against the backdrop of the prevalence of GLP-1 weight-loss drugs, the combined application of ACVR2A drugs and GLP-1 drugs is expected to preserve lean body mass while reducing fat, becoming a frontier direction for next-generation metabolic disease treatment.

V. Indication Expansion and Drug Development Trends of ACVR2A.

Looking to the future, research on the ACVR2A target will no longer be confined to a single field but will develop in a multi-dimensional and refined direction. First is the broadening of indications: in addition to pulmonary arterial hypertension, ACVR2A also plays important roles in diseases such as preeclampsia, obesity, and muscle atrophy. For example, ACVR2A expression is significantly downregulated in placental tissue of patients with preeclampsia, and it is expected to become a new therapeutic target in the future. Second is the refinement of drug development, which will evolve from simple fusion proteins to antibody drugs with higher specificity and explore differentiated strategies such as “receptor-side blockade and ligand-side neutralization.” Finally is the deepening of mechanistic research: with advances in gene editing and transcriptome analysis technologies, the specific regulatory details of ACVR2A in different microenvironments will be further revealed, providing a more solid theoretical foundation for next-generation innovative drugs.

VI. Conclusion.

In basic research and drug development related to ACVR2A, high-quality recombinant ACVR2A protein is a core tool for elucidating its binding mechanisms with ligands such as activin, myostatin, and GDF11 and for evaluating the activity of targeted drugs. The GST tag facilitates efficient purification through glutathione affinity chromatography and can serve as a detection tag for analyses such as enzyme-linked immunosorbent assay and surface plasmon resonance. To meet the needs of ACVR2A functional research and signaling pathway mechanism exploration, UIA provides ACVR2A GST Tag Protein, Human. This product is suitable for applications such as binding activity analysis of ACVR2A with ligands including activin and myostatin, research on the heterodimerization mechanism of ACVR2A with type I receptors, in vitro evaluation of Smad2/3 signaling pathway activation, and screening of ligand traps and targeted antibody drugs.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next